康恩贝：康恩贝集团减持公司股份合计2524万股，减持计划实施完毕

Summary of Key Points Core Viewpoint - 康恩贝 announced the completion of a share reduction plan by its major shareholder, 康恩贝集团, which involved the sale of over 25 million shares, representing approximately 1% of the company's total share capital [1]. Company Performance - For the first half of 2025, 康恩贝's revenue composition was as follows: manufacturing (pharmaceutical industry) accounted for 86.63%, commercial sales for 12.07%, and other businesses for 1.3% [1]. - As of the latest report, 康恩贝's market capitalization stands at 12.1 billion yuan [1]. Shareholder Activity - 康恩贝集团 reduced its holdings by 25,242,600 shares from October 23 to November 11, 2025, which is 1.000% of the total share capital at the time of the announcement and 0.999% of the current total share capital of 2,526,581,971 shares [1]. - The share reduction plan has now been fully implemented [1].